EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Scorecard

Which current developments should the committee understand?

Dose Diligence research deskSection 09 · Page 3 of 15Last updated 17 Nov 2026

Do not reuse a shortage-era compliance pack or an old regulatory deadline without checking it. The following findings affect the evidence requested for a November 2026 decision.

Verified developmentProcurement implication
FDA’s April 1, 2026 clarification states that semaglutide and tirzepatide are absent from the shortage and 503B bulks lists. The shortage database reviewed for this document did not list their injectable products as currently in shortage.Obtain a current, product-specific route assessment; historic shortage status is not a purchasing authorisation. (fda.gov)
The Fifth Circuit affirmed the challenged FDA delisting decisions in opinions dated August 27, 2026; the semaglutide opinion was revised September 1, 2026.Do not accept a general assertion that litigation restores shortage-era supply. Counsel should identify the actual operative order and any subsequent proceedings. (govinfo.gov)
FDA announced a proposal on April 30, 2026 not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list.Distinguish a proposal from a final determination. This review did not identify a subsequent final determination; that is a research limitation, not permission to compound. (fda.gov)
California introduced additional nonresident-pharmacy pharmacist-in-charge requirements effective July 1, 2026.A previously acceptable state-coverage file needs a new check against the current requirements. (pharmacy.ca.gov)
FDA currently publishes exemptions from specified DSCSA requirements for qualifying small dispensers through November 27, 2027. Its eligibility definition uses the owning company’s pharmacist/pharmacy-technician staffing as of November 27, 2026.Do not classify eligibility by the clinic’s number of prescribers, or treat relief from specified requirements as exemption from the entire DSCSA. (fda.gov)
On November 9, 2026, FDA announced required GLP-1 RA labeling changes concerning a potential increased risk of non-arteritic anterior ischemic optic neuropathy, a rare eye condition.Ask clinical leadership and the dispensing partner to demonstrate how new safety communications are reviewed and incorporated into appropriate materials and escalation procedures. (fda.gov)
Explore the table row by row

A working view of the research

FDA’s April 1, 2026 clarification states that semaglutide and tirzepatide are absent from the shortage and 503B bulks lists. The shortage database reviewed for this document did not list their injectable products as currently in shortage.

Procurement implication
Obtain a current, product-specific route assessment; historic shortage status is not a purchasing authorisation. (fda.gov)

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. govinfo.gov · Source 2 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
  3. fda.gov · Source 3 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  4. pharmacy.ca.gov · Source 4 ↗https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
  5. fda.gov · Source 5 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  6. fda.gov · Source 6 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
Section sources →